内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Braveheart Bio, Inc.

BRVE · Nasdaq · CIK 0002131524 · Healthcare · Biotechnology

内部人信号

85.8 / 100

10 位买方 · 13 条买入交易行 · $159.0M 买入总额

为什么有这个信号？

买方广度较强
买入规模较强
角色中等
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+35.0 / 35
买入规模+24.8 / 25
角色+13.0 / 20
近期性+3.0 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ 角色得分低 · 买入者中职位最高的是：CEO and President（CEO、董事长和持股 10% 以上的股东得分最低）
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN ATenPercentOwner
○●
Chimovits ErezDirector,TenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCDirector,TenPercentOwner
○●
Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.TenPercentOwner
○●
Jiangsu Hengrui Pharmaceuticals Co., Ltd.TenPercentOwner
○
Rickey James PaulChief Financial Officer
●
● 买入▼ 卖出○ 其他

Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方10
买入集中度41%最大买方： Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V. · $64.8M
聚集买入 · 15天10 insiders峰值活动： 2026-08-07–2026-08-07

Roles in the peak window: CEO and President, Chief Development Officer, Chief Financial Officer, Director, Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

85.8 / 100

最新留档分数

↓ -0.1 pts相对上一个留档快照
  1. 86.0
  2. 86.0
  3. 85.9
  4. 85.9
  5. 85.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

13买入
0卖出
6其他 Form 4 交易行
11SEC 申报 · 365天
买入13 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他6 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
-26.5%
3M
—
6M
—
12M
—

波动率与流动性

波动率
88.5%
Beta
—
平均每日成交额
USD 11.0M

估值

市值
USD 1.8B
P/E
—

基本面

利润率
—
ROE
—
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-09-03 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
4,128,974
上期报告
2,461,086
日均成交量
809,950
回补天数
5.1

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
2026-08-07Chimovits Erez买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A买入 (P)Common Stock1,100,000USD 18.00USD 19,800,000SEC 申报 ↗
2026-08-07Viehbacher Christopher买入 (P)Common Stock83,333USD 18.00USD 1,499,994SEC 申报 ↗
2026-08-07Rickey James Paul买入 (P)Common Stock27,777USD 18.00USD 499,986SEC 申报 ↗
2026-08-07Murdoch Travis买入 (P)Common Stock83,333USD 18.00USD 1,499,994SEC 申报 ↗
2026-08-07Malek David I买入 (P)Common Stock4,166USD 18.00USD 74,988SEC 申报 ↗
2026-08-07Lubner David Charles买入 (P)Common Stock55,555USD 18.00USD 999,990SEC 申报 ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.买入 (P)Common Stock3,600,000USD 18.00USD 64,800,000SEC 申报 ↗
2026-08-07Anderson Michele A.买入 (P)Common Stock1,111USD 18.00USD 19,998SEC 申报 ↗

Form 4 申报证据

19 transaction lines in the latest 365-day window; 19 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCC (C)Common Stock9,132,420USD —USD —SEC 申报 ↗
2026-08-07Chimovits Erez买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
展开近期 Form 4 证据 (15 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLC买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCC (C)Common Stock9,132,420USD —USD —SEC 申报 ↗
2026-08-07Chimovits Erez买入 (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC 申报 ↗
2026-08-07Chimovits ErezC (C)Common Stock9,132,420USD —USD —SEC 申报 ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A买入 (P)Common Stock1,100,000USD 18.00USD 19,800,000SEC 申报 ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN AC (C)Common Stock9,132,420USD —USD —SEC 申报 ↗
2026-08-07Jiangsu Hengrui Pharmaceuticals Co., Ltd.C (C)Common Stock7,420,091USD —USD —SEC 申报 ↗
2026-08-07Viehbacher Christopher买入 (P)Common Stock83,333USD 18.00USD 1,499,994SEC 申报 ↗
2026-08-07Rickey James Paul买入 (P)Common Stock27,777USD 18.00USD 499,986SEC 申报 ↗
2026-08-07Murdoch Travis买入 (P)Common Stock83,333USD 18.00USD 1,499,994SEC 申报 ↗
2026-08-07Malek David I买入 (P)Common Stock4,166USD 18.00USD 74,988SEC 申报 ↗
2026-08-07Lubner David Charles买入 (P)Common Stock55,555USD 18.00USD 999,990SEC 申报 ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.买入 (P)Common Stock3,600,000USD 18.00USD 64,800,000SEC 申报 ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.C (C)Common Stock17,123,287USD 0.00USD 0SEC 申报 ↗
2026-08-07Anderson Michele A.买入 (P)Common Stock1,111USD 18.00USD 19,998SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码BRVE
CIK0002131524
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史19 transaction lines from 2026-08-07 to 2026-08-07
13 P purchase lines · 0 S sale lines · 6 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.